rs2059807 — INSR INSR intronic variant

The Insulin Receptor Variant Linked to PCOS and Metabolic Risk

The insulin receptor (INSR) gene encodes the cell-surface receptor that binds insulin and triggers glucose uptake in muscle, fat, and liver. When this signaling cascade¹¹ signaling cascade
The insulin signaling pathway: insulin binds INSR → INSR autophosphorylates → IRS1/IRS2 activation → PI3K/AKT → GLUT4 translocation → glucose enters the cell works efficiently, blood sugar stays stable after meals. rs2059807 is an intronic variant — it does not change the protein directly — but it may alter INSR transcript splicing or expression levels in metabolically relevant tissues, influencing the sensitivity of cells to insulin's signal.

The Mechanism

As an intronic variant, rs2059807 does not produce an amino acid change. Its functional effect is likely regulatory²² regulatory
Intronic variants can create or destroy splice enhancer/silencer motifs, alter transcription factor binding sites within the intron, or influence expression via chromatin looping to nearby enhancers — affecting how much INSR protein is produced or which splice isoforms predominate. The INSR gene generates two major isoforms (IR-A and IR-B) through alternative splicing of exon 11; altered isoform balance shifts downstream signaling toward mitogenic versus metabolic outputs. Even modest reductions in insulin receptor abundance or signaling fidelity can drive compensatory hyperinsulinemia — the hallmark of insulin resistance.

The Evidence

The strongest evidence for rs2059807 comes from the PCOS field, where this locus was identified in a large-scale GWAS of over 10,000 cases and controls³³ large-scale GWAS of over 10,000 cases and controls
Chen et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 19p13.2. Nat Genet 2011:

• A meta-analysis of four independent studies⁴⁴ meta-analysis of four independent studies
  Feng et al. The association between polymorphism of INSR and polycystic ovary syndrome: a meta-analysis. Int J Mol Sci, 2015 encompassing 11,683 PCOS cases and 12,830 controls confirmed that rs2059807 is a robust susceptibility locus for PCOS in multiple ethnic cohorts.

• A prospective study in 2,082 Han Chinese women⁵⁵ prospective study in 2,082 Han Chinese women
  Tian et al. PCOS-GWAS Susceptibility Variants in THADA, INSR, TOX3, and DENND1A Are Associated With Metabolic Syndrome or Insulin Resistance. Front Endocrinol, 2020 showed that G-allele carriers (AG+GG) had a 27% increased risk of metabolic syndrome compared to AA homozygotes (OR 1.27, P=0.023), independent of age.

• In 253 Indian women with PCOS⁶⁶ 253 Indian women with PCOS
  Dakshinamoorthy et al. Association of GWAS identified INSR variants (rs2059807 & rs1799817) with polycystic ovarian syndrome in Indian women. Int J Biol Macromol, 2020, rs2059807 minor-allele carriers showed elevated LH (6.32 vs 4.97 mIU/mL), higher estradiol (116 vs 65 pg/mL), and lower HDL-cholesterol (50 vs 64 mg/dL) compared to controls — a hormonal and metabolic profile consistent with impaired insulin signaling.

• In the Framingham Heart Study (n=1,475 controls, 396 cases)⁷⁷ Framingham Heart Study (n=1,475 controls, 396 cases)
  Parekh et al. Insulin receptor variants and obesity-related cancers in the Framingham Heart Study. Cancer Causes Control, 2015, rs2059807 was the most significant INSR variant associated with obesity-related cancers (colorectal OR 1.5, breast OR 1.29), highlighting broader metabolic consequences beyond reproductive phenotypes.

The overall evidence is replicated across multiple populations and phenotypes but remains at the moderate tier — effect sizes are modest (OR 1.2–1.3 range), and the causal mechanism (exactly how this intronic variant alters INSR function) has not been characterized at the molecular level.

Practical Actions

For G-allele carriers, the primary concern is insulin resistance and its downstream consequences: elevated fasting glucose, dyslipidemia (especially low HDL and elevated triglycerides), and — in women — PCOS susceptibility. The actionable levers are those that directly improve insulin sensitivity through mechanisms independent of lifestyle platitudes: specifically, monitoring fasting insulin and glucose to detect early compensatory hyperinsulinemia, and choosing dietary patterns (low-glycemic, lower refined carbohydrate) that reduce insulin demand on a receptor that may be less abundant or responsive.

GG homozygotes, who carry the greatest G-allele dose, benefit most from periodic fasting insulin testing — a marker rarely ordered in routine care but highly informative for detecting insulin resistance before fasting glucose rises above normal.

Interactions

rs2059807 compounds biologically with rs1799817 (INSR His1058Arg missense variant), the other major INSR GWAS hit for PCOS. These two variants are in modest linkage disequilibrium and may independently tag different aspects of INSR dysfunction — rs1799817 affects receptor kinase activity while rs2059807 likely affects expression. Carrying risk alleles at both positions may have an additive effect on insulin resistance, though published compound analyses are limited.

The variant also interacts with the broader insulin signaling network: IRS1 rs1801278 and TCF7L2 rs7903146 (energy-weight category) affect overlapping pathways. Individuals carrying G here alongside TCF7L2 T alleles face compounded impairment of glucose-stimulated insulin secretion and peripheral insulin sensitivity.